Features of the vaginal microbiota in recurrent urinary tract infections in childhood

BACKGROUND. Currently, there is a stable deterioration in the somatic health of preschool-age girls, which creates a real threat to the realization of reproductive function in the future. The state of vaginal microbiocenosis in preschool girls suffering from recurrent urinary tract infections (UTIs) remains a little-studied problem.THE AIM: to assess the state of the vaginal biotope in preschool girls suffering from recurrent UTIs.PATIENTS AND METHODS. 92 girls aged 3-6 years were examined, of which: group 1 (n=32) - patients with recurrent UTI; group 2 (n=30) - patients with rare UTI; group 3 (n=30) - girls of 1,2 health groups. Vaginal microbiocenosis was assessed by quantitative PCR using the «Femoflor-17 test system». Statistical analysis was performed using the application program "Statistica 6.0 for Windows".RESULTS. Facultative anaerobes predominate in the vaginal microbiocenosis of patients with UTI, the absolute content of which is significantly higher in patients with the recurrent course (p <0.05). The relative number of facultative anaerobes is significantly higher in patients with rare UTIs (p<0.05). In patients with recurrent UTI, the absolute and relative content of obligate anaerobes is lower than in patients with rare UTI and girls from the control group. The index of total bacterial mass in patients with UTI, compared with girls of the control group, is significantly higher (p<0.05). In patients with UTI, an increase in the colonies of the Enterobacteriacea family and a decrease in obligate anaerobes were determined in comparison with similar indicators of girls in the control group.CONCLUSION. The presence of recurrent UTI in preschool girls is a risk factor for the development of the severe vaginal dysbiotic condition. Rare UTIs can also be a risk of developing vaginal dysbiosis. Real-time multi-dimensional PCR provides quantitative and qualitative characteristics of the conditionally pathogenic flora of the vaginal biotope.

Download Full-text

A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections

Current Urology ◽

10.1159/000499248 ◽

2020 ◽

Vol 14 (3) ◽

pp. 130-134

Author(s):

Andrew Brodie ◽

Omar El-Taji ◽

Ibrahim Jour ◽

Charlotte Foley ◽

Damian Hanbury

Keyword(s):

Urinary Tract ◽

Urinary Tract Infections ◽

Primary Outcome Measure ◽

Effective Treatment Option ◽

Recurrent Utis ◽

Recurrent Uti ◽

Recurrent Urinary Tract Infections ◽

Pre Treatment ◽

The Uk ◽

Tract Infections

Objectives: To present our experience with the long-term preventive effect of immunotherapy with Uro-Vaxom® on recurrent urinary tract infections (UTI) in adult patients. Materials and Methods: Retrospective analysis of 79 patients with recurrent UTI treated with Uro-Vaxom. Recurrent UTIs were defined as ≥ 2 infections in 6 months or ≥ 3 in 12 months. Patients received a 6 mg Uro-Vaxom capsule daily for 90 days followed by discontinuation for 3 months and then administration for the first 10 days of subsequent months 7, 8 and 9 as a ‘booster' regime. The primary outcome measure was the number of UTIs encountered in the 12 months pre-treatment compared to 12 months post-treatment. Results: There was a significant decrease in the mean number of UTIs in the year following initiation of Uro-Vaxom® compared to the year preceding administration 3.14 versus 1.53 (p < 0.05) respectively. Conclusion: Uro-Vaxom represents a safe and effective treatment option for prophylaxis of recurrent UTIs. In the UK, Uro-Vaxom is currently unlicensed. This study adds to a growing body of evidence in favor of non-antibiotic immune-prophylaxis for recurrent UTI.

Download Full-text

Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections Among Patients With Neurogenic Bladder: A Randomized Controlled Trial

Clinical Infectious Diseases ◽

10.1093/cid/ciz1207 ◽

2019 ◽

Cited By ~ 3

Author(s):

Aurélien Dinh ◽

Marie-Charlotte Hallouin-Bernard ◽

Benjamin Davido ◽

Adrien Lemaignen ◽

Frédérique Bouchand ◽

...

Keyword(s):

Urinary Tract ◽

Neurogenic Bladder ◽

Urinary Tract Infections ◽

Bacterial Resistance ◽

Controlled Trial ◽

Group Versus ◽

Control Group ◽

Recurrent Urinary Tract Infections ◽

Cord Injury ◽

Tract Infections

Abstract Background Recurrent urinary tract infections (R-UTIs) are the main cause of morbidity and hospitalizations in subjects with neurogenic bladder (NB) due to spinal cord injury (SCI). We evaluated the efficacy of weekly oral cyclic antibiotic (WOCA) prophylaxis (ie, the alternate weekly administration of 2 antibiotics) in preventing R-UTIs. Methods Randomized (1:1), open-label, superiority-controlled trial compared WOCA prophylaxis to no prophylaxis (control) for 6 months in patients with NB due to SCI, using clean intermittent self-catheterization, and suffering from R-UTIs. Primary outcome was incidence of symptomatic antibiotic-treated UTIs. Secondary outcomes were number of febrile UTIs, number of hospitalizations, WOCA tolerance, antibiotic consumption, number of negative urine cultures, and emergence of bacterial resistance in urinary, intestinal, and nasal microbiota. Results Forty-five patients were either allocated to the WOCA group (n = 23) or the control group (n = 22). Median (IQR) incidence of symptomatic antibiotic-treated UTIs was 1.0 (0.5–2.5) in the WOCA group versus 2.5 (1.2–4.0) (P = .0241) in the control group. No febrile UTIs were recorded in the WOCA group versus 9 (45.0%) (P < .001) in the control group. The median number of additional antibiotic treatment was 0.0 (IQR, 0.0–2.0) versus 3.0 (2.0–5.0) (P = .004) in the WOCA and control groups, respectively. Only few adverse events were reported. No impact on emergence of bacterial resistance was observed. Conclusions WOCA is efficient and well tolerated in preventing R-UTIs in SCI patients. In our study, we did not observe any emergence of antibiotic resistance in digestive and nasal microbiological cultures. Clinical Trials Registration NCT01388413.

Download Full-text

PHYSICAL AND SEXUAL DEVELOPMENT OF ADOLESCENT GIRLS WITH RECURRENT URINARY TRACT INFECTIONS

Nephrology (Saint-Petersburg) ◽

10.24884/1561-6274-2018-22-5-77-82 ◽

2018 ◽

Vol 22 (5) ◽

pp. 77-82

Author(s):

G. M. Letifov ◽

Yu. Yu. Chebotareva ◽

E. G. Gorban’ ◽

Z. A. Kostoeva

Keyword(s):

Urinary Tract ◽

Urinary Tract Infections ◽

Adolescent Girls ◽

Sexual Development ◽

Sexual Disorders ◽

Control Group ◽

Recurrent Urinary Tract Infections ◽

Gynecological Examination ◽

Frequent Relapses ◽

Tract Infections

THE AIM: to study the peculiarities of physical and sexual development of adolescent girls with recurrent urinary tract infections.PATIENTS AND METHODS. Examined 70 adolescent girls aged 16 – 18 years with exacerbation of chronic pyelonephritis (CP): 1 group (n=43) – with rare relapse history (relapses pyelonephritis from 1 to 3 times during the period of the disease, rCP) and group 2 (n=27) with frequent relapses (more than 3 times a year, fCP). The control group (n=30) consisted of practically healthy adolescent girls of the same age. Anthropometry, evaluation of sexual development, specialized gynecological examination, determination of serum hormones, ultrasound examination of the reproductive organs were carried out. Statistical processing of research results was performed using the software packages Statistica 6.0 ("StatSoft Inc", USA) and statistical analysis Microsoft Office Excel 2003" ("Microsoft Corporation", USA).RESULTS. It was revealed that in patients with rCP, compared with girls of the 1st and control groups, there was a lower growth, a decrease in the basic pelvic dimensions, against the background of a tendency to increase weight, there were some variants of sexual disorders, more often than in other groups there were early pubarche and later menarche. Established significant increase in the level of LH, testosterone and DHEA-S in the background of hypoprogesteronemia. The rate of hyperpolymenorrhea, uterine bleeding and primary oligomenorrhea was significantly higher, were often found emerging polycystic ovary syndrome and chronic vulvovaginitis.CONCLUSION. Patients with frequent recurrence of urinary tract infections have a variety of constitutional features, a tendency to metabolic syndrome development, expressed hormonal status violations. The detected increase in testosterone levels contributes to the emerging polycystic ovaries syndrome development.

Download Full-text

Pycnogenol® Supplementation Prevents Recurrent Urinary Tract Infections/Inflammation and Interstitial Cystitis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/9976299 ◽

2021 ◽

Vol 2021 ◽

pp. 1-8

Author(s):

A. Ledda ◽

S. Hu ◽

M. R. Cesarone ◽

G. Belcaro ◽

M. Dugall ◽

...

Keyword(s):

Urinary Tract ◽

Side Effects ◽

Interstitial Cystitis ◽

Urinary Tract Infections ◽

Recurrent Uti ◽

Recurrent Urinary Tract Infections ◽

Standard Management ◽

Tract Infections ◽

Open Pilot

This open pilot registry study aimed to evaluate and compare the prophylactic effects of Pycnogenol® or cranberry extract in subjects with previous, recurrent urinary tract infections (UTI) or interstitial cystitis (IC). Methods. Inclusion criteria were recurrent UTI or IC. One subject group was supplemented with 150 mg/day Pycnogenol®, another with 400 mg/day cranberry extract, and a group served as a control in a 2-month open follow-up. Results. 64 subjects with recurrent UTI/IC completed the study. The 3 groups of subjects were comparable at baseline. All subjects had significant symptoms (minor pain, stranguria, repeated need for urination, and lower, anterior abdominal pain) at inclusion. In the course of the study, the subjects reported no tolerability problems or side effects. The incidence of UTI symptoms, in comparison with the period before inclusion in the standard management (SM) group, decreased significantly; there was a more pronounced decrease in the rate of recurrent infections in the Pycnogenol® group ( p < 0.05 ). The improvement in patients supplemented with Pycnogenol® was significantly superior to the effects of cranberry. At the end of the study, all subjects in the Pycnogenol® group were infection-free ( p < 0.05 vs. cranberry). Significantly, more subjects were completely symptom-free after 2 months of management with Pycnogenol® (20/22) than with SM (18/22) and cranberry (16/20). Conclusions. This pilot registry suggests that 60 days of Pycnogenol® supplementation possibly decrease the occurrence of UTIs and IC without side effects and with an efficacy superior to cranberry.

Download Full-text